Description
Eltoprazine hydrochloride is the hydrochloride form of Eltoprazine which is a serenic or antiaggressive agent. It acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor with Ki values of 40, 52 and 81 nM for 5-HT1A, 5-HT1B and 5-HT2C receptors respectively. It has been shown to reduce L-DOPA-induced dyskinesias in experimental models of Parkinson's Disease and in human patients, although this effect was accompanied by a partial worsening of the therapeutic effect of l-dopa in vivo. It is used as a novel drug for the treatment of anxiety as well as other neurological and mental disorders. It was developed by PsychoGenics and Amarantus Bioscience, Inc. It is in clinical stage 3